What this is
- How it works
- Makes the kidneys flush extra sugar and salt into the urine. Started as a diabetes drug; now also used for heart and kidney disease.-gliflozin: sodium-glucose co-transporter inhibitors WHO name stem
- How it’s given
- “10mg mizagliflozin capsules orally administered TID for 28 days”In the company’s words, NCT07760961 on ClinicalTrials.gov
- Tested for
- Postbariatric Hypoglycemia
- Main trialPhase 2
- “VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.”In the company’s words, NCT07760961 on ClinicalTrials.gov
Other drugs for Postbariatric Hypoglycemia
Coming up1
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2027 | Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia | |
| Phase 2Completed | 17 Feb 2023 | Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects | |
| Phase 2Completed | 1 May 2024 | Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026